

**100
CASES**

in
**Obstetrics
and
Gynaecology**

Third Edition



Cecilia Bottomley,
Ruth MacSwan and
Janice Rymer

Series Editor: Janice Rymer

 **CRC Press**
Taylor & Francis Group



in
**Obstetrics
and
Gynaecology**

100 Cases in Obstetrics and Gynaecology presents 100 obstetric- or gynaecology-related scenarios commonly seen by medical students and junior doctors in the emergency department, outpatient clinic or on the ward. A succinct summary of the patient's history, examination and initial investigations – including photographs where relevant – is followed by questions on the diagnosis and management of each case. The answer includes a detailed discussion on each topic, with further illustration where appropriate, providing an essential revision aid as well as a practical guide for students and junior doctors.

Making speedy and appropriate clinical decisions, and choosing the best course of action to take as a result, is one of the most important and challenging parts of training to become a doctor. These true-to-life cases, fully revised and updated for this third edition, will teach students and junior doctors to recognize important obstetric and gynaecological conditions, and to develop their diagnostic and management skills.

100 Cases

About the Series

Making speedy and appropriate clinical decisions and choosing the best course of action to take as a result is one of the most important and challenging parts of training to become a doctor. The real-life cases presented in the 100 Cases series encompass emergency, ward, and outpatient and community scenarios, and have been designed specifically to help medical students and junior doctors to develop their diagnostic and management skills.

100 Cases in Dermatology

Rachael Morris-Jones, Ann-Marie Powell, Emma Benton

100 Cases in Radiology

Robert Thomas, James Connelly, Christopher Burke

100 Cases in Orthopaedics and Rheumatology

Parminder J Singh, Catherine Swales

100 Cases in Surgery, 2E

James Gossage, Bijan Modarai, Arun Sahai, Richard Worth, Kevin G Burnand

100 Cases in Clinical Ethics and Law, 2E

Carolyn Johnston, Penelope Bradbury

100 Cases in Paediatrics, 2E

Ronny Cheung, Aubrey Cunningham, Simon Drysdale, Joseph Raine, Joanna Walker

100 Cases in General Practice, 2E

Anne E Stephenson, Martin Mueller, John Grabinar

100 Cases in Psychiatry, 2E

Barry Wright, Subodh Dave, Nisha Dogra

100 Cases in Emergency Medicine and Critical Care

Eamon Shamil, Praful Ravi, Dipak Mistry

100 Cases in Clinical Pharmacology, Therapeutics and Prescribing

Kerry Layne, Albert Ferro

100 Cases in Acute Medicine, 2E

Henry Fok, Kerry Layne, Adam Nabeebaccus

100 Cases in Clinical Pathology and Laboratory Medicine, 2E

Eamon Shamil, Praful Ravi, Ashish Chandra

100 Diagnostic Dilemmas in Clinical Medicine, 2E

Kerry Layne

100 Cases in Obstetrics and Gynaecology, 3E

Cecilia Bottomley, Ruth MacSwan, Janice Rymmer

For more information about this series please visit: <https://www.routledge.com/100-Cases/book-series/CRCONEHUNCAS>



Third Edition

in
**Obstetrics
and
Gynaecology**

Cecilia Bottomley MBBChir MRCOG MD
Consultant Gynaecologist
and Honorary Associate Professor
University College London Hospitals (UCLH)
London, UK

Ruth MacSwan
ST6 in Obstetrics and Gynaecology
and Clinical Fellow in Obstetric Ultrasound
University College London Hospitals (UCLH)
London, UK

Janice Rymer MD FRCOG FRANZCOG FHEA
Dean of Student Affairs
and Professor of Obstetrics and Gynaecology
King's College School of Medicine
and Consultant Gynaecologist
Guy's and St Thomas' NHS Foundation Trust
London, UK

100 Cases Series Editor
Janice Rymer



CRC Press

Taylor & Francis Group
Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

Third edition published 2025
by CRC Press
2385 NW Executive Center Drive, Suite 320, Boca Raton, FL 33431

and by CRC Press
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN

CRC Press is an imprint of Taylor & Francis Group, LLC

© 2025 Cecilia Bottomley, Ruth Macswan and Janice Rymer

This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have been made to publish reliable data and information, neither the author[s] nor the publisher can accept any legal responsibility or liability for any errors or omissions that may be made. The publishers wish to make clear that any views or opinions expressed in this book by individual editors, authors or contributors are personal to them and do not necessarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for use by medical, scientific or health-care professionals and is provided strictly as a supplement to the medical or other professional's own judgement, their knowledge of the patient's medical history, relevant manufacturer's instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the relevant national drug formulary and the drug companies' and device or material manufacturers' printed instructions, and their websites, before administering or utilizing any of the drugs, devices or materials mentioned in this book. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as to advise and treat patients appropriately. The authors and publishers have also attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, access www.copyright.com or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. For works that are not available on CCC please contact mpkbookspermissions@tandf.co.uk

Trademark notice: Product or corporate names may be trademarks or registered trademarks and are used only for identification and explanation without intent to infringe.

ISBN: 9781032480077 (hbk)
ISBN: 9781032397733 (pbk)
ISBN: 9781003386933 (ebk)

DOI: 10.1201/9781003386933

Typeset in Baskerville
by Deanta Global Publishing Services, Chennai, India

Access the Support Material: www.routledge.com/9781032397733

CONTENTS

<i>Preface to the Third Edition</i>	<i>ix</i>
<i>Acknowledgements</i>	<i>x</i>

Section 1: General Gynaecology

Case 1	Intermenstrual Bleeding	3
Case 2	Infertility	7
Case 3	Amenorrhoea	9
Case 4	Primary Infertility	11
Case 5	Infertility	13
Case 6	Shortness of Breath and Abdominal Pain	15
Case 7	Abdominal Swelling	21
Case 8	Abnormal Cervical Smear	23
Case 9	Anaemia	25
Case 10	Absent Periods	27
Case 11	Postmenopausal Bleeding	31
Case 12	Painful Periods	33
Case 13	Postcoital Bleeding	35
Case 14	Recurrent Miscarriage	37
Case 15	Pelvic Pain	41
Case 16	Infertility	43
Case 17	Heavy Menstrual Bleeding	47
Case 18	Urinary Incontinence	49
Case 19	Absent Periods	51
Case 20	Abdominal and Back Pain	53
Case 21	Postoperative Confusion	55
Case 22	Postmenopausal Bleeding	57
Case 23	Pelvic Pain	61
Case 24	Primary Amenorrhoea	63
Case 25	Permanent Contraception	65
Case 26	Labile Mood and Abdominal Pain	67
Case 27	Cervical Cancer	71
Case 28	Urinary Incontinence	75
Case 29	Pelvic Pain	77
Case 30	Early Menarche	79
Case 31	Excessive Hair Growth	81

Section 2: Emergency Gynaecology

Case 32	Pain and the Intrauterine System	85
Case 33	Bleeding in Pregnancy	87
Case 34	Pelvic Pain	89
Case 35	Vulval Swelling	91
Case 36	Abdominal Pain	93
Case 37	Urinary Retention	95
Case 38	Abdominal Pain	99
Case 39	Abdominal Pain	101
Case 40	Abdominal Pain and Vaginal Discharge	103

Section 3: Early Pregnancy

Case 41	Ectopic Pregnancy Management	107
Case 42	Early Pregnancy Ultrasound	111
Case 43	Midtrimester Complications	113
Case 44	Pain and Bleeding in Early Pregnancy	117
Case 45	Bleeding in Early Pregnancy	121
Case 46	Bleeding in Early Pregnancy	125
Case 47	Bleeding in Early Pregnancy	129
Case 48	Vomiting in Pregnancy	131

Section 4: General Obstetrics

Case 49	Pain in Pregnancy	137
Case 50	Illegal Drug Use in Pregnancy	139
Case 51	Antenatal Screening	143
Case 52	Epilepsy in Pregnancy	147
Case 53	Obesity in Pregnancy	151
Case 54	Glucose Tolerance Test	153
Case 55	Antenatal Care	157
Case 56	Previous Caesarean Section	161
Case 57	Group B Streptococcus	163
Case 58	Twin Pregnancy	165
Case 59	Chicken Pox Exposure in Pregnancy	167
Case 60	Bleeding in Pregnancy	171
Case 61	Breech Presentation	173
Case 62	Antenatal Screening	177
Case 63	Elective Caesarean Section Request	179

Case 64	Postpartum Chest Pain	183
Case 65	Antenatal Ultrasound	187
Case 66	HIV in Pregnancy	189
Case 67	Itching in Pregnancy	191
Case 68	Tiredness in Pregnancy	193
Case 69	Diabetes in Pregnancy	195

Section 5: Peripartum Care and Obstetric Emergencies

Case 70	Palpitations and Shortness of Breath in Pregnancy	201
Case 71	Reduced Fetal Movements	203
Case 72	Absent Fetal Movements	207
Case 73	Labour	211
Case 74	Peripartum Collapse	213
Case 75	Postpartum Bleeding	215
Case 76	Perineal Wound Infection	217
Case 77	Labour	219
Case 78	Labour	223
Case 79	Labour	227
Case 80	Pain and Fever in Pregnancy	231
Case 81	Headache in Pregnancy	235
Case 82	Prolonged Pregnancy	237
Case 83	Pain in Pregnancy	241
Case 84	Delivery	245
Case 85	Headache in Pregnancy	249
Case 86	Labour	251
Case 87	Postpartum Bleeding	253
Case 88	Labour	257
Case 89	Pain in Pregnancy	259
Case 90	Perineal Tear	261
Case 91	Fits in Pregnancy	265
Case 92	Breathlessness in Pregnancy	267
Case 93	Blood Pressure and Pregnancy	273
Case 94	Labour	275

Section 6: Family Planning and Sexual Health

Case 95	Postnatal Contraception	281
Case 96	Contraception	285
Case 97	Unprotected Intercourse	289

Case 98	Vaginal Discharge	293
Case 99	Teenage Contraception	295
Case 100	Intermenstrual Bleeding	297
<i>Index</i>		301

Bonus cases are available for download at www.routledge.com/9781032397733

Case E1	Pain in Early Pregnancy
Case E2	Pain in Early Pregnancy
Case E3	Bleeding in Early Pregnancy
Case E4	Antenatal Screening

PREFACE TO THE THIRD EDITION

This book is now in its third edition, a testimony to the popularity of the 100 Cases Series, and the Obstetrics and Gynaecology edition, as a teaching and learning tool.

Reflecting the most up-to-date practice, this edition contains several new cases to reflect contemporary diagnostic and therapeutic tools, while retaining the cases reported to be most useful. The authors are established teachers of undergraduate and postgraduate obstetrics and gynaecology, working daily with and thoroughly understanding the learning needs of medical students and junior doctors in the field.

Real clinical scenarios, from which these cases originate, remain the best way to stimulate thought and understand clinical and pathological processes. Through our question and answer format, the reader is encouraged to practice the skill of formulating investigation and treatment plans as they would in everyday practice.

In this edition we have developed several areas further which reflect the changing landscape of the field, such as pregnancy in the older woman and the management of complex maternal medical conditions in pregnancy.

Engagement of women with the informed consent process and communication skills in general, which are covered extensively, are vitally important in clinical exams.

We have ensured that all of the cases incorporate published national guidance from national bodies such as the National Institute for Health and Care Excellence (NICE) and the Royal College of Obstetricians and Gynaecologists (RCOG) or from specialist societies such as the British Society of Colposcopy and Cervical Pathology (BSCCP).

As with earlier editions, the book is written with both medical students and junior clinicians in their obstetrics and gynaecology placements in mind and has been found to be an ideal tool for both.

Our experience has found that there are always moments in the day between theatre cases, while considering a patient just seen in clinic or after taking a patient history in the emergency department when the cases are pertinent. The simple indexing system means it is easy to find a case to refer to that relates to your current patient, whether that be bleeding in early pregnancy, fibroid management, reduced fetal movements or a postnatal pyrexia.

The cases vary in complexity to reinforce important or common subject areas. The book should reinforce knowledge and build confidence in some areas, challenge and stimulate thought in others and continue to provide an invaluable tool for learning in the specialty of obstetrics and gynaecology.

Cecilia Bottomley
Ruth MacSwan
Janice Rymer

ACKNOWLEDGEMENTS

The authors would like to acknowledge and thank their colleagues for their help with illustrations and useful suggestions for cases for the first, second and third editions of this book.

Section 1

GENERAL GYNAECOLOGY



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

CASE 1: INTERMENSTRUAL BLEEDING

History

A 48-year-old woman presents with intermenstrual bleeding for 2 months. Episodes of bleeding occur any time in the cycle. This is usually fresh red blood and much lighter than a normal period. It can last for 1–6 days. There is no associated pain. She has no hot flushes or night sweats. She is sexually active and has not noticed vaginal dryness.

She has three children and has used the progesterone-only pill for contraception for 5 years.

Her last smear test was 2 years ago and all smears have been normal. She takes no medication and has no other relevant medical history.

Examination

The abdominal examination is unremarkable. Speculum examination shows a slightly atrophic-looking vagina and cervix but there are no apparent cervical lesions and there is no current bleeding.

On bimanual examination the uterus is non-tender and of normal size, axial and mobile. There are no palpable adnexal masses.



INVESTIGATIONS

		<i>Normal Range</i>
Haemoglobin	127 g/L	117–157 g/L
White cell count	$4.5 \times 10^9/L$	$3.5\text{--}11 \times 10^9/L$
Platelets	$401 \times 10^9/L$	$150\text{--}440 \times 10^9/L$

Transvaginal ultrasound scan and hydrosalpingography are shown in Figure 1.1.




Figure 1.1 Transvaginal ultrasound image showing midsagittal view of the uterine cavity after installation of saline (hydrosalpingography).



QUESTIONS

- What is the diagnosis and differential diagnosis?
- How would you further investigate and manage this woman?

ANSWER 1

The diagnosis is of an endometrial polyp, shown in the ultrasound image as a mass, surrounded by the instilled fluid, within the endometrial cavity (Figure 1.1). These can occur in women of any age, although they are more common in older women and may be asymptomatic or cause irregular bleeding or discharge. The aetiology is uncertain and the vast majority are benign. In this specific case all the differential diagnoses are effectively excluded by the history and examination.



DIFFERENTIAL DIAGNOSIS FOR INTERMENSTRUAL BLEEDING

- Cervical malignancy
- Cervical ectropion
- Endocervical polyp
- Atrophic vaginitis
- Pregnancy
- Irregular bleeding related to the contraceptive pill
- Pelvic inflammatory disease

Management

Any woman should be investigated if bleeding occurs between periods over three cycles or more. In women over the age of 40 years, serious pathology, in particular endometrial carcinoma, should be excluded.

Asymptomatic polyps are common and generally safe to manage expectantly if they demonstrate benign features on ultrasound scan (single feeder vessel, smooth walls, normal surrounding endometrium).

In this case, however, the polyp needs to be removed to eliminate the cause of the bleeding.

Management involves outpatient or day case hysteroscopy, and resection of the polyp under direct vision using a diathermy loop or other resection technique (Figure 1.2). This allows certainty that the polyp had been completely excised and also allows full inspection of the rest of the cavity to check for any other lesions or suspicious areas. In some settings, where hysteroscopic facilities are not available, a dilatation and curettage may be carried out with blind avulsion of the polyp with polyp forceps. This was the standard management in the past but is not the gold standard now, for the reasons explained.

The polyp should be sent for histological analysis to confirm its benign nature.



KEY POINTS

- Any woman over the age of 40 years should be investigated if bleeding occurs between the periods for more than three cycles, to exclude serious pathology, in particular endometrial carcinoma.
- Hysteroscopy is rarely indicated for women under the age of 40 years unless pathology is suspected from an ultrasound scan.



Figure 1.2 Hysteroscopic appearance of endometrial polyp prior to resection.



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

CASE 2: INFERTILITY

History

A 31-year-old woman has been trying to conceive for nearly 3 years without success. Her last period started 7 months ago and she has been having periods sporadically for about 5 years. She bleeds for 2–7 days and the periods occur at intervals of 2–9 months. There is no dysmenorrhoea but occasionally the bleeding is heavy.

She has been pregnant once in the past at the age of 19 years but that pregnancy was terminated for personal reasons. She had a laparoscopy several years ago for pelvic pain, which showed a normal pelvis.

Cervical smears have always been normal and there is no history of sexually transmitted infection.

The woman was diagnosed with irritable bowel syndrome when she was 25, after thorough investigation for other bowel conditions. She currently uses metoclopramide to increase gut motility, and antispasmodics.

Her partner is fit and well, and has two children by a previous relationship. Neither partner drinks alcohol or smokes.



INVESTIGATIONS

		<i>Normal Range</i>
Follicle-stimulating hormone	3.1 IU/L	Day 2–5 1–11 IU/L
Luteinizing hormone	2.9 IU/L	Day 2–5 0.5–14.5 IU/L
Prolactin	1274 mu/L	90–520 mu/L
Testosterone	1.4 nmol/L	0.8–3.1 nmol/L
Thyroid-stimulating hormone	4.1 mu/L	0.5–7 mu/L
Free thyroxine	17 pmol/L	11–23 pmol/L

Day 21 progesterone was requested but no period occurred for 3 months and therefore the test was not performed.



QUESTIONS

- What is the diagnosis and its aetiology?
- How would you further investigate and manage this couple?

ANSWER 2

The infertility is likely to be secondary to anovulation. Normal testosterone and gonadotrophins and high prolactin suggest the likely case of the anovulation to be hyperprolactinaemia. Hyperprolactinaemia may be physiological in breast-feeding, pregnancy and stress. The commonest causes of pathological hyperprolactinaemia are tumours and idiopathic hypersecretion, but it may also be due to drugs, hypothyroidism, ectopic prolactin secretion or chronic renal failure. In this case the metoclopramide is the cause, as it is a dopamine antagonist (dopamine usually acts via the hypothalamus to cause inhibition of prolactin secretion, and if this is interrupted, prolactin is secreted to excess). Galactorrhoea is not a common symptom of hyperprolactinaemia, occurring in less than half of affected women.



DRUGS ASSOCIATED WITH HYPERPROLACTINAEMIA (DUE TO DOPAMINE ANTAGONIST EFFECTS)

- Metoclopramide
- Phenothiazines (e.g. chlorpromazine, prochlorperazine, thioridazine)
- Reserpine
- Methyl dopa
- Omeprazole, ranitidine, bendrofluazide (rare associations)

The metoclopramide should be stopped and the woman reviewed after 4–6 weeks to ensure that the periods have restarted and that the prolactin level has returned to normal. It would be advisable also at that stage to carry out a day 21 progesterone level to confirm ovulatory cycles.

If the cycles do not resume or the prolactin level does not normalize, then further investigation is needed to exclude other causes of hyperprolactinaemia, such as a pituitary micro- or macroadenoma.

As with all women attempting to conceive, she should have her rubella immunity checked and should be advised to take periconceptual folic acid until 12 weeks of pregnancy to reduce the risk of neural tube defects. She should also be encouraged to be up to date with her COVID and flu immunizations.

If the woman fails to conceive after correction of hyperprolactinaemia, then a full fertility investigation should be planned with semen analysis and tubal patency testing (laparoscopy and dye test, hysterosalpingogram or hysterosalpingo-contrast sonography [HyCoSy]).



KEY POINTS

- A full drug history should be elicited in women with amenorrhoea or infertility.
- Galactorrhoea occurs in less than half of women with hyperprolactinaemia.
- Day 21 progesterone over 30 nmol/L is suggestive of ovulation.

CASE 3: AMENORRHOEA

History

A 32-year-old woman complains that she has not had a period for 3 months. Four home pregnancy tests have all been negative. She started her periods at the age of 15 years and until 30 years she had a normal 27-day cycle. She had one daughter by normal delivery 2 years ago, following which she breast-fed for 6 months. After that she had normal cycles again for several months and then her periods stopped abruptly. She was using the progesterone-only pill for contraception while she was breast-feeding and stopped 6 months ago as she is keen to have another child. She reports symptoms of dryness during intercourse and has experienced sweating episodes at night as well as episodes of feeling extremely hot at any time of day. There is no relevant gynaecological history. The only medical history of note is that she has been hypothyroid for 10 years and takes thyroxine 100 mcg per day. She does not take any alcohol, smoke or use recreational drugs.

Examination

Examination findings are unremarkable.



INVESTIGATIONS

		<i>Normal Range</i>
Haemoglobin	122 g/L	117–157 g/L
White cell count	$5.1 \times 10^9/L$	$3.5\text{--}11 \times 10^9/L$
Platelets	$203 \times 10^9/L$	$150\text{--}440 \times 10^9/L$
Thyroid-stimulating hormone	3.6 mu/L	0.5–7 mu/L
Free thyroxine	21 pmol/L	11–23 pmol/L
Follicle-stimulating hormone	45 IU/L	Day 2–5 1–11 IU/L
Luteinizing hormone	30 IU/L	Day 2–5 0.5–14.5 IU/L
Prolactin	401 mu/L	90–520 mu/L
Oestradiol	87 pmol/L	Day 2–5 70–510 pmol/L
Testosterone	2.3 nmol/L	0.8–3.1 nmol/L



QUESTIONS

- What is the diagnosis?
- What further investigations should be performed?
- What are the key points in the management of this woman?

ANSWER 3

This woman has symptoms of amenorrhoea as well as hypo-oestrogenic vasomotor symptoms and vaginal dryness. The diagnosis is of premature ovarian insufficiency, confirmed by the very high gonadotrophin levels. High levels occur because the ovary is resistant to the effects of gonadotrophins, and negative feedback to the hypothalamus and pituitary causes increasing secretion to try to stimulate the ovary. Sheehan's syndrome (pituitary necrosis after postpartum haemorrhage) would also cause amenorrhoea but would have inhibited breast-feeding and all menstruation since delivery.

Premature ovarian failure (before the age of 40 years) occurs in 1 per cent of women and has significant physical and psychological consequences. It may be idiopathic but a familial tendency is common. In some cases it is an autoimmune condition (associated with hypothyroidism in this case). Disorders of the X chromosome can also be associated.



EFFECTS OF PREMATURE MENOPAUSE

- *Hypo-oestrogenic effects:*
 - Vaginal dryness
 - Vasomotor symptoms (hot flushes, night sweats)
 - Osteoporosis
 - Increased cardiovascular risk
- *Psychological and social effects:*
 - Infertility
 - Feeling of inadequacy as a woman
 - Feelings of premature ageing and need to take HRT
 - Impact on relationships

Further Investigation

Osteoporosis may be prevented with continuous oestrogen replacement, but progesterone should also be given simultaneously (cyclically or continuously) to prevent the increased risk of endometrial carcinoma from unopposed oestrogen. Bone scan is necessary for baseline bone density and to help in monitoring the effects of hormone replacement. Chromosomal analysis and Fragile X-premutation testing is recommended for any woman experiencing premature ovarian insufficiency to identify rare cases due to fragile X syndrome or Turner's syndrome mosaicism. An autoimmune screen should be performed.

Management

Osteoporosis may be prevented with oestrogen replacement, with progesterone protection of the uterus. Traditional HRT preparations or the combined oral contraceptive pill continuously are effective. In terms of future fertility, this woman's options are *in vitro* fertilization (IVF) with donor oocytes, adoption or the acceptance of only having one child. Occasionally, premature ovarian failure is a fluctuating condition (resistant ovary syndrome) whereby the ovaries may function intermittently. Contraception should therefore be used if it would be undesirable to become pregnant. Patient support organizations are a good source for women experiencing such an unexpected and stigmatizing diagnosis.



KEY POINTS

- Premature ovarian failure (<40 years) occurs in 1 per cent of women.
- Oestrogen replacement is essential for bone and cardiovascular protection.
- It may be possible to conceive with IVF using donor oocytes.

CASE 4: PRIMARY INFERTILITY

History

A couple attends the gynaecology clinic because of failure to conceive. They stopped using condoms for contraception 19 months ago. There are no apparent sexual difficulties, and they have been having intercourse two to three times per week. In the last 6 months, ovulation has been confirmed by the woman reporting a positive home urinary ovulation kit test, and they have been having intercourse around this time.

The woman is 28 years old, with regular 29-day menstrual cycles and no previous gynaecological problems. Both the woman and her partner are generally healthy and have been together for 7 years. Neither reports any previous sexually transmitted infection.

Examination

The woman's investigations are normal, with normal gonadotrophins (LH and FSH), and confirmation of ovulation with a day 21 progesterone test. Chlamydia test is negative and she is immune to rubella. Hysterosalpingogram confirms patent fallopian tubes and normal morphology of the endometrial cavity.



INVESTIGATIONS

The semen analysis for her partner is as follows:

<i>Parameter</i>		<i>Normal Range (World Health Organization)</i>
Semen volume	3.2 mL	>1.5 mL
Total sperm number	9.6 million	39 million per ejaculate
Sperm concentration	3 million/mL	>15 million/mL
Total motility (progressive and non-progressive)	9%	>40%
Live spermatozoa	45%	>58%
Sperm morphology (normal forms)	3%	>4%



Figure 4.1 Transvaginal ultrasound scan of the ovary.



QUESTIONS

- What does the semen analysis show?
- What further information should you ascertain from the man?
- What does the ultrasound show and what is its significance in this case?
- What further investigation and management would you plan for the management of this couple's infertility?

ANSWER 4

Semen Analysis Interpretation

Normal ranges for semen characteristics are published by the World Health Organization (WHO). The nomenclature applied to abnormal semen quality depends on the degree of abnormality and the specific type of abnormality. In this case the sample would suggest oligoastheno-terato-zoospermia (total number and concentration of spermatozoa, and percentages of both progressively motile and morphologically normal spermatozoa, all below the lower reference limits).

Further Information to Be Ascertained

The history from the man is insufficient. Further enquiries should include:

- Occupation (infertility has been associated with occupational exposure to chemicals and with scrotal temperature)
- Smoking history
- Alcohol intake
- Previous medical history (cancer treatment, cystic fibrosis, mumps or testicular torsion may affect fertility)
- Medication use (in particular anabolic steroid use as affects spermatogenesis)
- Recent viral illness (may also affect spermatogenesis)

It should be confirmed that the semen sample was provided following the recommended procedures:

- Collected after at least 48 h but no more than 7 days of sexual abstinence
- Delivered to the laboratory within 1 h of production
- Collected by masturbation and ejaculated into a clean glass or plastic container, protected from extremes of temperature (below 20 degrees or above 40 degrees)

Ultrasound Findings

The image shows an ovary which is polycystic in morphology. This is not a relevant factor for this couple as she has regular periods and the day 21 blood test confirms ovulation.

Further Investigation and Management

The abnormal sperm quality is the likely cause of infertility, but the semen analysis must be repeated to confirm that it is not a transient effect, e.g. of a recent viral illness. Causes of oligospermia may be pretesticular (such as pituitary tumours, smoking or medication), testicular (such as varicocele, trauma, mumps or Y chromosome deletions) or post-testicular (such as prostatitis or cystic fibrosis causing vas deferens obstruction). Referral to an andrologist can be useful in these cases as some causes of oligospermia are amenable to treatment.

The man should also be examined for scrotal size and morphology. Testicular biopsy may be indicated to rule out pathology. Percutaneous sperm aspiration from the testis can be carried out in a man with complete azoospermia from an obstructive cause (not relevant for this couple where the man does have some sperm in the seminal fluid).

Assuming the semen quality remains poor on repeat analysis after 3 months, then the couple will need assisted conception with *in vitro* fertilization and intracytoplasmic sperm injection (direct injection of a single sperm into an egg) to achieve a pregnancy.

CASE 5: INFERTILITY

History

A 37-year-old woman is seen in the clinic because of infertility. She is gravida 2 para 1 having had a daughter 13 years ago, and a miscarriage 2 years later. She separated from her former husband and has now married again and is keen to conceive, especially as her new partner has no children.

Her last period started 45 days ago. She says that her periods are sometimes regular but at other times she has missed a period for up to 3 months. The bleeding is moderate and lasts for up to 4 days. There is no history of pelvic pain or dyspareunia, and no irregular bleeding or discharge. Alcohol intake is minimal and she does not smoke or take other drugs. There is no medical history of note and she takes no regular medication.

Her partner is 34 years old and is also fit and healthy with no significant history of ill-health or medications.

Examination

There are no abnormal features on examination of either partner.



INVESTIGATIONS (DURING THE NEXT MENSTRUAL CYCLE)

		<i>Normal Range</i>
Day 3 follicle-stimulating hormone (FSH)	11.1 IU/L	Day 2–5 1–11 IU/L
Day 3 luteinizing hormone	6.8 IU/L	Day 2–5 0.5–14.5 IU/L
Prolactin	305 mu/L	90–520 mu/L
Testosterone	1.3 nmol/L	0.8–3.1 nmol/L
Day 21 progesterone	13 nmol/L	

Semen analysis report: Normal volume, count, normal forms and motility.

Hysterosalpingogram report: The uterine cavity is of normal shape with a smooth regular outline. Contrast medium is seen to fill both uterine tubes symmetrically and free spill of dye is confirmed bilaterally.

Transvaginal ultrasound scan report: The uterus is anteverted with no congenital abnormalities, uterine fibroids or polyps visualized. Both ovaries are of normal morphology, volume and mobility. Two follicles are seen on the left ovary and one follicle is present on the right ovary.



QUESTIONS

- What is the cause of the infertility?
- What are the further investigation and management options?

ANSWER 5

Women with irregular periods often do not ovulate. Anovulation in this case is confirmed by the low day 21 progesterone level. The commonest cause of anovulation is polycystic ovaries, but in this case the ovaries show normal morphology and the androgen levels are normal.

The noticeable abnormality is the high FSH level and the fact that only a small number of follicles are visualized at ultrasound scan. This is suggestive of anovulation from premature failure of ovarian function. The woman is not menopausal because she still has periods, although irregular, and the FSH is only marginally raised. However, it is known that FSH levels above 10 IU/L are associated with a poor prognosis for conception using the woman's own ova.

Further Investigation

The FSH should be repeated, as it is possible that this could be a sporadic result or poorly timed sample, and therefore confirmation is needed before continuing on to treatment.

Anti-Mullerian hormone (AMH) is a further test of ovarian reserve and ovarian responsiveness in women with infertility. It decreases with number of ovarian antral follicles and it can be used to predict likelihood of ovarian response and pregnancy with assisted conception. Optimal fertility is associated with AMH levels of 28–48 pmol/L, whereas levels less than 5 pmol/L are suggestive of poor success rates with natural or assisted conception.

Management

As there is such a poor prognosis for conception either naturally or with *in vitro* fertilization using the woman's own oocytes, she should be counselled about assisted conception using donor eggs. Donated oocytes are fertilized with the partner's sperm and then implanted into the uterus. The woman needs appropriate luteal phase support, most commonly with progesterone pessaries.



COUNSELLING ISSUES FOR THIS COUPLE

- *Psychological:*
 - The woman may feel that her ovaries are 'ageing' prematurely and this may have an effect on her self-esteem and sexuality.
 - The stress associated with assisted conception is significant and many couples find that this in itself puts a large burden on their relationship.
- *Funding:* Public funding may not be available as the woman already has one child.
- *Consideration of alternative options:* Adoption, surrogacy and acceptance of not being able to have a child together should be explored with the couple.



KEY POINTS

- FSH above 10 IU/L is associated with poor prognosis for fertility.
- Infertile couples should be encouraged to explore all options, including accepting childlessness and adoption as well as assisted conception techniques.
- Low AMH is associated with poor fertility. Values less than 5 pmol/L are associated with a very poor chance of IVF success.

CASE 6: SHORTNESS OF BREATH AND ABDOMINAL PAIN

History

A 72-year-old woman has been admitted with shortness of breath. On further questioning she says that she has been unwell for about 8 weeks. She has decreased appetite and nausea when she eats. She has lost weight but her abdomen feels swollen. She has generalized dull abdominal pain and constipation, which is unusual for her. There are no urinary symptoms.

She has always been healthy with no previous hospital admissions. She is a widow and did not have any children. Her periods stopped at 52 years and she has had no postmenopausal bleeding. She has never taken hormone replacement therapy.

Examination

She appears pale and breathless on talking. Chest expansion is reduced on the right side, with dullness to percussion and decreased air entry at the right base. The abdomen is generally distended with shifting dullness. There is a palpable mass which seems to be arising from the pelvis. Speculum examination is normal, but on bimanual palpation there is a fixed left iliac fossa mass of about 10 cm diameter.



INVESTIGATIONS

		<i>Normal Range</i>
Haemoglobin	92 g/L	117–157 g/L
Mean cell volume	82 fL	80–99 fL
White cell count	$4.1 \times 10^9/L$	$3.5\text{--}11 \times 10^9/L$
Platelets	$197 \times 10^9/L$	$150\text{--}440 \times 10^9/L$
Sodium	135 mmol/L	135–145 mmol/L
Potassium	4.0 mmol/L	3.5–5 mmol/L
Urea	5.1 mmol/L	2.5–6.7 mmol/L
Creatinine	89 mmol/L	70–120 mmol/L
Alanine transaminase	18 IU/L	5–35 IU/L
Aspartate transaminase	17 IU/L	5–35 IU/L
Alkaline phosphatase	78 IU/L	30–300 IU/L
Bilirubin	12 mmol/L	3–17 mmol/L
Albumin	30 g/L	35–50 g/L
CA-125	118 ku/L	<30 ku/L

Chest X-ray and abdominal computerized tomography (CT) scan are shown in Figures 6.1 and 6.2, respectively.



QUESTIONS

- What is the likely diagnosis?
- How should this woman be further investigated?
- If the diagnosis is confirmed how should she be managed?



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>



Figure 6.1 Chest X-ray.




Figure 6.2 Abdominal CT scan.

ANSWER 6

The history and examination are suggestive of a right pleural effusion and ascites. The presence of a pelvic mass would suggest that this is due to an ovarian or bowel problem. The chest X-ray confirms the effusion, and the CT shows a left-sided pelvic tumour and ascites. There are also solid areas in the anterior abdominal wall that represent omental infiltration by the tumour.

CA-125 is a non-specific marker for ovarian carcinoma. The diagnosis is therefore likely to be that of ovarian cancer which commonly presents with systemic symptoms when metastatic disease is already evident.



CONFIRMATION OF THE DIAGNOSIS AND MANAGEMENT

The surgical aphorism 'there is no diagnosis without a surgical diagnosis' means that tissue needs to be obtained to confirm the diagnosis. As the suspected tumour has already spread beyond the ovaries, then biopsy does not risk spread of disease and should be performed under radiological guidance, targeting any of the tumour deposits. Where not possible, laparotomy should be performed with three objectives:

1. Obtaining tissue for diagnosis.
2. Staging the disease according to the extent of tissue involvement.
3. Primary debulking – to perform a total abdominal hysterectomy and bilateral salpingo-oophorectomy and to reduce all abdominal tumour deposits to a volume of less than 2 cm. This allows optimal effect of chemotherapy following surgery. Lymph node dissection and omental resection are usually part of the procedure.

Prior to any treatment this woman also needs drainage of her pleural effusion for symptomatic relief and optimization for anaesthetic. She will need referral to her local multidisciplinary gynae oncology team which consists of gynaecologists, oncologists, radiologists, cancer specialist nurses and pathologists. Any extensive operating will be carried out in a large tertiary unit.

The prognosis for ovarian cancer is poor, as most women present at stage 3 or 4.



OVARIAN CANCER STAGING AND PROGNOSIS

Stage			Prognosis (5-Year Survival Rate)
Stage 1 Confined to the ovaries	1A	One ovary affected, ovarian capsule is intact	90%
	1B	Both ovaries affected, ovarian capsules intact	
	1C	Ovarian capsule is ruptured, tumour on ovarian surface or malignant cells detected in ascites or peritoneal washings	
Stage 2 Pelvic spread	2A	Extension or implantation into the uterus and/or fallopian tubes (no malignant cells in ascites/peritoneal washings)	65%
	2B	Extension to another organ in the pelvis (no malignant cells in ascites/peritoneal washings)	
	2C	As for 2A/B plus malignant cells in ascites/peritoneal washings	

Stage		Prognosis (5-Year Survival Rate)
Stage 3 Peritoneal metastasis outside the pelvis and/or regional lymph node metastasis (includes liver capsule metastasis)	3A	Microscopic peritoneal metastasis beyond the pelvis
	3B	Macroscopic peritoneal metastasis beyond the pelvis (max. diameter 2 cm)
	3C	Macroscopic peritoneal metastasis beyond the pelvis (max. diameter >2 cm) and/or distant lymph node metastases
Stage 4 Distant metastasis beyond the peritoneal cavity (or liver parenchymal metastasis)		35%
		20%



KEY POINTS

- CA-125 is a non-specific marker for ovarian cancer.
- Ovarian cancer commonly presents late (stage 3/4) and prognosis is poor.
- Staging and primary treatment is by laparotomy, total abdominal hysterectomy, bilateral salpingoophorectomy and debulking.
- Neoadjuvant chemotherapy (preoperative chemotherapy to shrink the tumour mass down so that debulking surgery is more likely to be successful) may also be considered depending on the extent of disease on imaging.
- Chemotherapy is often effective adjuvant therapy.



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

CASE 7: ABDOMINAL SWELLING

History

A 36-year-old African-Caribbean woman has noticed abdominal swelling for 10 months. She has to wear larger clothes and people have asked her if she is pregnant, which she finds distressing as she has in fact been trying to conceive. She has no abdominal pain and her bowel habit is normal. She feels nauseated when she eats large amounts. She has urinary frequency but no dysuria or haematuria.

Her periods are regular, every 27 days, and have always been heavy, with clots and flooding on the second and third days. She has never received any treatment for her heavy periods. She has been with her partner for 7 years and despite not using contraception she has never been pregnant.

Examination

The woman has a very distended abdomen. A smooth firm mass is palpable extending from the symphysis pubis to midway between the umbilicus and the xiphisternum (equivalent to a 32-week size pregnancy). It is non-tender and mobile. It is not fluctuant and it is not possible to palpate beneath the mass. On speculum examination it is not possible to visualize the cervix. Bimanual examination reveals a non-tender firm mass occupying the pelvis.



INVESTIGATIONS

		<i>Normal Range</i>
Haemoglobin	63 g/L	117–157 g/L
Mean cell volume	68 fL	80–99 fL
White cell count	$4.9 \times 10^9/L$	$3.5\text{--}11 \times 10^9/L$
Platelets	$267 \times 10^9/L$	$150\text{--}440 \times 10^9/L$

Magnetic resonance images (MRIs) of the abdomen and pelvis are shown in Figures 7.1 and 7.2.




Figure 7.1 MRI of the abdomen and pelvis.




Figure 7.2 MRI of the abdomen and pelvis.



QUESTIONS

- What is the diagnosis?
- How would you further investigate and manage this woman?